
Volitionrx Limited (VNRX) Stock Forecast & Price Target
Volitionrx Limited (VNRX) Analyst Ratings
Bulls say
VolitionRX Ltd is positioning itself for revenue growth and expanded market adoption through collaborations in the pharmaco-epigenetics space, particularly with major diagnostic and pharmaceutical companies. The successful validation of the Nu.Q Lung Cancer Test represents a significant milestone that could enhance the attractiveness of its technology for strategic partnerships. Additionally, the adoption of its Nu.Q Discover biomarkers by over 1,000 veterinary hospitals in Japan highlights strong market demand and underscores the company's capacity to increase revenue through innovation and automation in diagnostics.
Bears say
VolitionRX Ltd is engaged in developing blood tests utilizing its Nucleosomics platform, which aims to improve disease diagnosis and monitoring, particularly in the context of cancers and NETosis-related conditions. The company is currently facing challenges, as indicated by its study focusing on reducing false-positive rates in pulmonary nodule differentiation—an area plagued by issues leading to unnecessary invasive procedures. These challenges highlight potential limitations in the efficacy and reliability of its diagnostic tests, raising concerns about the company’s market competitiveness and overall financial performance.
This aggregate rating is based on analysts' research of Volitionrx Limited and is not a guaranteed prediction by Public.com or investment advice.
Volitionrx Limited (VNRX) Analyst Forecast & Price Prediction
Start investing in Volitionrx Limited (VNRX)
Order type
Buy in
Order amount
Est. shares
0 shares